

Patient - PACT

New Clinical Trial and Research



| | |
|---|---|
| Trial title | A study to test how taking BI 1015550 for 12 weeks affects lung function in people with idiopathic pulmonary fibrosis (IPF) |
| Trial synopsis | <p>This research is testing a new treatment for idiopathic pulmonary fibrosis (IPF) called BI 1015550. The purpose of the research project is to investigate a potential new medication, BI 1015550, which is a type of medication called PDE4 inhibitor. This Study will determine how taking BI 1015550 for 12 weeks affects lung function in people with IPF. This project will also test if BI 1015550 can be tolerated and is safe for IPF patients to take.</p> <p>Patients will be included in the trial and eligibility criteria will be assessed during the screening period. After this period, the eligible patients will be assigned by random choice to receive either the investigational drug BI 1015550 or the placebo and assessed for 12 weeks.</p> |
| Investigational medicinal product, comparator and randomisation | BI 1015550 |
| Disease target | People with Idiopathic Pulmonary Fibrosis (IPF) |
| Sponsor | Boehringer Ingelheim |
| Duration | 12 weeks treatment |
| Trial Status | <i>Recruiting</i> |
| Lead site(s) in Australia | Dr Ian Glaspole – The Alfred Hospital, Melbourne, VIC |
| Lead site(s) in New Zealand | NA |
| Additional sites | Royal Prince Alfred Hospital, Sydney, NSW. |
| Contact | pactcoordinator@cre-pf.org.au |